Patent US4935343A successfully refreshed from Google Patents.
US4935343A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibodies for interleukin-1β
Assignee: Syntex USA LLC
•
Filing: 1986-08-08
•
Granted: 1990-06-19
•
Expires: 2006-08-08
Abstract
Abstract The present invention is concerned with novel monoclonal antibodies which bind to Interleukin-1 beta and do not bind to Interleukin-1 beta . The antibodies bind to Interleukin-1 beta and block receptor binding and biological activity. The antibodies find use in, for example, diagnostic methods such as an assay for the detection of Interleukin-1 beta .
Inventors
- 👤 Anthony C. Allison
- 👤 Elsie M. Eugui
- 👤 John S. Kenney
- 👤 Marvin P. Masada
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 22:46
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/24; C07K16/244; C07K16/245; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/68; G01N33/6863; G01N33/6869; C07K2317/00; C07K2317/70; C07K2317/73; Y; Y10; Y10S; Y10S435/00; Y10S435/81; Y10S435/962; Y10S436/00; Y10S436/807; Y10S436/808
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
73 words
An immunoassay method for the detection of Interleukin-1β which comprises: contacting a sample suspected of containing Interleukin-1β with a monoclonal antibody that binds to Interleukin-1β and does not bind to Interleukin-1α; that blocks binding of Interleukin-1β to Interleukin-1 receptors; and, that binds to Interleukin-1β and blocks biological activity of Interleukin-1β, in order to form an immune complex; and determining the presence of said immune complex in order to detect Interleukin-1β in said sample.
Claim 2
Dependent Claim
73 words
An immunoassay method for the detection of Interleukin-1β which comprises: contacting a sample suspected of containing Interleukin-1β with a monoclonal antibody that binds to Interleukin-1β and does not bind to Interleukin-1α; that blocks binding of Interleukin-1β to Interleukin-1 receptors; and, that binds to Interleukin-1β and blocks biological activity of Interleukin-1β, in order to form an immune complex; and determining the presence of said immune complex in order to detect Interleukin-1β in said sample.
Claim 3
Dependent Claim
52 words
The method of claim 1 wherein said monoclonal antibody is selected from the group of monoclonal antibodies obtained from the group consisting of hybrid continuous cell lines having identifying characteristics of ILB1-H6 (ATCC designation HB 102019), ILB1-H21 (ATCC designation HB 10220), ILB1-H34 (ATCC designation HB 10221) and ILB1-H67 (ATCC designation HB 10222).
Claim 4
Dependent Claim
14 words
The method of claim 1 wherein said monoclonal antibody is conjugated to a label.
Claim 5
Dependent Claim
27 words
The method of claim 1 wherein said sample is a body fluid selected from the group consisting of whole blood, lymphatic fluid, serum, plasma, saliva, and urine.
Claim 6
Dependent Claim
32 words
A monoclonal antibody that binds to Interleukin-1β and does not bind to Interleukin-1α; that blocks binding of Interleukin-1β to Interleukin-1 receptors; and, that binds to Interleukin-1β and blocks biological activity of Interleukin-1β.
Claim 7
Dependent Claim
32 words
A monoclonal antibody that binds to Interleukin-1β and does not bind to Interleukin-1α; that blocks binding of Interleukin-1β to Interleukin-1 receptors; and, that binds to Interleukin-1β and blocks biological activity of Interleukin-1β.
Claim 8
Dependent Claim
27 words
The monoclonal antibody of claim 5 which is the antibody obtained from a hybrid continuous cell line having identifying characteristics of ILB1-H6 and ATCC designation HB 10219.
Claim 9
Dependent Claim
27 words
The monoclonal antibody of claim 5 which is the antibody obtained from a hybrid continuous cell line having identifying characteristics of ILB1-H21 and ATCC designation HB 10220.
Claim 10
Dependent Claim
27 words
The monoclonal antibody of claim 5 which is the antibody obtained from a hybrid continuous cell line having identifying characteristics of ILB1-H34 and ATCC designation HB 10221.
Claim 11
Dependent Claim
27 words
The monoclonal antibody of claim 5 which is the antibody obtained from a hybrid continuous cell line having identifying characteristics of ILB1-H67 and ATCC designation HB 10222.
Claim 12
Dependent Claim
10 words
The monoclonal antibody of claim 5 conjugated to a label.
Claim 13
Dependent Claim
28 words
The monoclonal antibody of claim 10 wherein said label is selected from the group consisting of enzymes, radioisotopes, particulate labels, chromogens, chemiluminescers, fluorescers, coenzymes, free radicals, and bacteriophages.
Claim 14
Dependent Claim
15 words
A hybrid continuous cell line having identifying characteristics of expressing the antibody of claim 5.
Claim 15
Dependent Claim
39 words
A hybrid continuous cell line selected from the group consisting of hybrid continuous cell lines having identifying characteristics of ILB1-H6 (ATCC designation HB 10219), ILB1-H21 (ATCC designation HB 10220), ILB1-H34 (ATCC designation HB 10221), ILB1-H67 (ATCC designation HB 10222).
Claim 16
Dependent Claim
39 words
A hybrid continuous cell line selected from the group consisting of hybrid continuous cell lines having identifying characteristics of ILB1-H6 (ATCC designation HB 10219), ILB1-H21 (ATCC designation HB 10220), ILB1-H34 (ATCC designation HB 10221), ILB1-H67 (ATCC designation HB 10222).
Claim 17
Dependent Claim
19 words
A kit for use in an immunoassay comprising in one or more containers the monoclonal antibody of claim 5.
Claim 18
Dependent Claim
14 words
The kit of claim 14 wherein said monoclonal antibody is conjugated to a label.
Claim 19
Dependent Claim
27 words
The kit of claim 15 wherein said label is selected from the group consisting of enzymes, radioisotopes, particulate labels, chromogens, fluorescers, chemiluminescers, coenzymes, free radicals, and bacteriophages.
Claim 20
Dependent Claim
36 words
The kit of claim 14 wherein said monoclonal antibody is unlabeled and said kit further comprises a conjugate of a specific binding partner of said monoclonal antibody and a label capable of producing a detectable signal.
Claim 21
Dependent Claim
14 words
The kit of claim 14 wherein said monoclonal antibody is bound to a support.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-06-18 | 1993-12-18 | 1994-06-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-06-18 | 1997-12-18 | 1998-06-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-06-18 | 2001-12-18 | 2002-06-19 | $7700.00 | Window Closed / Lapsed |